{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T20:37:01Z","timestamp":1772311021046,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["13XP5029A"],"award-info":[{"award-number":["13XP5029A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011748","name":"Phospholipid Research Center","doi-asserted-by":"publisher","award":["AKO-2019-070\/2-1"],"award-info":[{"award-number":["AKO-2019-070\/2-1"]}],"id":[{"id":"10.13039\/501100011748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011748","name":"Phospholipid Research Center","doi-asserted-by":"publisher","award":["PLU-2017-056\/2-1"],"award-info":[{"award-number":["PLU-2017-056\/2-1"]}],"id":[{"id":"10.13039\/501100011748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejpb.2022.11.025","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T03:46:31Z","timestamp":1669952791000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Formulating elafibranor and obeticholic acid with phospholipids decreases drug-induced association of SPARC to extracellular vesicles from LX-2 human hepatic stellate cells"],"prefix":"10.1016","volume":"182","author":[{"given":"Cristina","family":"Zivko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finja","family":"Witt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Koeberle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Fuhrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2022.11.025_b0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0010","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jhep.2018.05.011","article-title":"Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies","volume":"69","author":"Pimpin","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0015","doi-asserted-by":"crossref","unstructured":"N. Ndugga, T.G. Lightbourne, K. Javaherian, J. Cabezas, N. Verma, A.S. Barritt, R. Bataller, Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA, BMJ Open. 7 (2017) e013620. https:\/\/doi.org\/10.1136\/bmjopen-2016-013620.","DOI":"10.1136\/bmjopen-2016-013620"},{"key":"10.1016\/j.ejpb.2022.11.025_b0020","doi-asserted-by":"crossref","unstructured":"R.A. Vreman, A.J. Goodell, L.A. Rodriguez, T.C. Porco, R.H. Lustig, J.G. Kahn, Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: A microsimulation model, BMJ Open. 7 (2017) e013543. https:\/\/doi.org\/10.1136\/bmjopen-2016-013543.","DOI":"10.1136\/bmjopen-2016-013543"},{"key":"10.1016\/j.ejpb.2022.11.025_b0025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MCG.0000000000000116","article-title":"World Gastroenterology Organisation Global Guidelines","volume":"48","author":"LaBrecque","year":"2014","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/liv.13682","article-title":"Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening","volume":"38","author":"Marcellin","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.ejpb.2022.11.025_b0035","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5604\/16652681.1226814","article-title":"Management strategies for liver fibrosis","volume":"16","author":"Altamirano-Barrera","year":"2017","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0045","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1001\/jama.2018.17365","article-title":"Diagnosis and management of nonalcoholic fatty liver disease","volume":"320","author":"Paul","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ejpb.2022.11.025_b0050","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejpb.2022.11.025_b0055","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1007\/s10620-016-4254-7","article-title":"Targeting hepatic fibrosis in autoimmune hepatitis","volume":"61","author":"Montano-Loza","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"10.1016\/j.ejpb.2022.11.025_b0060","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","article-title":"Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis","volume":"40","author":"Czaja","year":"2004","journal-title":"J. Hepatol., Elsevier"},{"key":"10.1016\/j.ejpb.2022.11.025_b0065","first-page":"S3","article-title":"Primary biliary cholangitis: medical and specialty pharmacy management update","volume":"22","author":"Bowlus","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.ejpb.2022.11.025_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonistcCenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2022.11.025_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105889","article-title":"A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trials."},{"key":"10.1016\/j.ejpb.2022.11.025_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105922","article-title":"Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design","volume":"89","author":"Anstee","year":"2020","journal-title":"Contemp. Clin. Trials."},{"key":"10.1016\/j.ejpb.2022.11.025_b0085","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of Tropifexor (LJN452), a highly potent non-bile acid FXR Agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2022.11.025_b0090","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0095","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s10620-016-4128-z","article-title":"Novel pharmacotherapy options for NASH","volume":"61","author":"Ratziu","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejpb.2022.11.025_b0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/bmb\/ldw031","article-title":"Non-alcoholic fatty liver disease in 2016","volume":"119","author":"Townsend","year":"2016","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.ejpb.2022.11.025_b0105","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/liv.13270","article-title":"The therapeutic landscape of non-alcoholic steatohepatitis","volume":"37","author":"Perazzo","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.ejpb.2022.11.025_b0110","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2022.11.025_b0115","first-page":"G336","article-title":"Investigating fibrosis and inflammation in an ex vivo NASH murine model","volume":"318","author":"Gore","year":"2020","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/13543784.2020.1668375","article-title":"Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Westerouen Van Meeteren","year":"2020","journal-title":"Expert Opin. Investig. Drugs."},{"key":"10.1016\/j.ejpb.2022.11.025_b0125","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejpb.2022.11.025_b0130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"T\u00f8lb\u00f8l","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0135","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.apsb.2018.11.004","article-title":"Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis","volume":"9","author":"Zhou","year":"2019","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.ejpb.2022.11.025_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-45178-z","article-title":"Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob\/ob mouse model of biopsy-confirmed NASH","volume":"9","author":"Roth","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2022.11.025_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154338","article-title":"The role of peroxisome proliferator-activated receptors (PPAR) in immune responses","volume":"114","author":"Christofides","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.ejpb.2022.11.025_b0150","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.3390\/ijms19103032","article-title":"Identification of a novel PPAR-\u03b3 agonist through a scaffold tuning approach","volume":"19","author":"Gim","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2022.11.025_b0155","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.2337\/diabetes.54.8.2460","article-title":"Therapeutic roles of peroxisome proliferator-activated receptor agonists","volume":"54","author":"Staels","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.ejpb.2022.11.025_b0160","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/8755122516687122","article-title":"Obeticholic acid","volume":"33","author":"Smith","year":"2017","journal-title":"J. Pharm. Technol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0165","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2022.11.025_b0170","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/jpet.104.079665","article-title":"Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid x receptor ligand, in estrogen-induced cholestasis","volume":"313","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2022.11.025_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105911","article-title":"Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad 3","volume":"77","author":"Fan","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0180","doi-asserted-by":"crossref","first-page":"33453","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2022.11.025_b0185","unstructured":"GENFIT, Press Release\u00a0: Provides Initial Update on Corporate Strategy, Press Release. (2020)."},{"key":"10.1016\/j.ejpb.2022.11.025_b0190","unstructured":"Intercept, Intercept receives complete response letter from FDA for obeticholic acid for the treatment of fibrosis due to NASH., Press Release. (2020)."},{"key":"10.1016\/j.ejpb.2022.11.025_b0195","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1734-1140(11)70576-X","article-title":"Activity of essential phospholipids (EPL) from soybean in liver diseases","volume":"63","author":"Gundermann","year":"2011","journal-title":"Pharmacol. Reports."},{"key":"10.1016\/j.ejpb.2022.11.025_b0200","first-page":"99","article-title":"Essential phospholipids as a supportive adjunct in the management of patients with NAFLD, Arab","volume":"16","author":"Dajani","year":"2015","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0205","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/pharmaceutics11120676","article-title":"Synergy of phospholipid\u2014drug formulations significantly deactivates profibrogenic human hepatic stellate cells","volume":"11","author":"Valentino","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2022.11.025_b0210","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejpb.2022.11.025_b0215","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.ejpb.2022.11.025_b0225","doi-asserted-by":"crossref","first-page":"156","DOI":"10.20517\/2394-5079.2017.27","article-title":"Advances in the diagnosis and treatment of liver fibrosis","volume":"3","author":"Cheng","year":"2017","journal-title":"Hepatoma Res."},{"key":"10.1016\/j.ejpb.2022.11.025_b0230","doi-asserted-by":"crossref","first-page":"1648167","DOI":"10.1080\/20013078.2019.1648167","article-title":"Extracellular vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature","volume":"8","author":"Witwer","year":"2019","journal-title":"J. Extracell. Vesicles."},{"key":"10.1016\/j.ejpb.2022.11.025_b0235","doi-asserted-by":"crossref","unstructured":"C. Th\u00e9ry et al., Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines, J. Extracell. Vesicles. 7 (2018) 1535750. https:\/\/doi.org\/10.1080\/20013078.2018.1535750.","DOI":"10.1080\/20013078.2018.1535750"},{"key":"10.1016\/j.ejpb.2022.11.025_b0240","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/cas.13222","article-title":"Extracellular vesicles as trans-genomic agents: Emerging roles in disease and evolution","volume":"108","author":"Kawamura","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejpb.2022.11.025_b0245","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s42003-019-0300-2","article-title":"Exosome-mediated horizontal gene transfer occurs in double-strand break repair during genome editing","volume":"2","author":"Ono","year":"2019","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejpb.2022.11.025_b0250","doi-asserted-by":"crossref","unstructured":"I.K. Herrmann, M.J.A. Wood, G. Fuhrmann, Extracellular vesicles as a next-generation drug delivery platform, Nat. Nanotechnol. 2021 167. 16 (2021) 748\u2013759. https:\/\/doi.org\/10.1038\/s41565-021-00931-2.","DOI":"10.1038\/s41565-021-00931-2"},{"key":"10.1016\/j.ejpb.2022.11.025_b0255","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1039\/C8LC01123K","article-title":"Extracellular vesicles as cancer liquid biopsies: From discovery, validation, to clinical application","volume":"19","author":"Zhao","year":"2019","journal-title":"Lab Chip."},{"key":"10.1016\/j.ejpb.2022.11.025_b0260","doi-asserted-by":"crossref","first-page":"070","DOI":"10.1055\/s-0038-1676122","article-title":"Extracellular vesicles in liver diseases: diagnostic, prognostic, and therapeutic application","volume":"39","author":"Urban","year":"2019","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ejpb.2022.11.025_b0265","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharmthera.2017.02.020","article-title":"Exosomes: Therapy delivery tools and biomarkers of diseases","volume":"174","author":"Barile","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2022.11.025_b0270","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s42003-022-04123-z","article-title":"Tracking matricellular protein SPARC in extracellular vesicles as a non-destructive method to evaluate lipid-based antifibrotic treatments","volume":"5","author":"Zivko","year":"2022","journal-title":"Commun. Biol."},{"issue":"12","key":"10.1016\/j.ejpb.2022.11.025_b0275","doi-asserted-by":"crossref","first-page":"166235","DOI":"10.1016\/j.bbadis.2021.166235","article-title":"Nuclear receptors in liver fibrosis","volume":"1867","author":"K\u00f6nigshofer","year":"2021","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"10.1016\/j.ejpb.2022.11.025_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2020.121320","article-title":"Analytical profiling and stability evaluation of liposomal drug delivery systems: A rapid UHPLC-CAD-based approach for phospholipids in research and quality control","volume":"220","author":"Weber","year":"2020","journal-title":"Talanta"},{"key":"10.1016\/j.ejpb.2022.11.025_b0285","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1073\/pnas.1216182110","article-title":"Arachidonoyl-phosphatidylcholine oscillates during the cell cycle and counteracts proliferation by suppressing Akt membrane binding","volume":"110","author":"Koeberle","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejpb.2022.11.025_b0290","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1096\/fj.14-268474","article-title":"Role of p38 mitogen-activated protein kinase in linking stearoyl-CoA desaturase-1 activity with endoplasmic reticulum homeostasis","volume":"29","author":"Koeberle","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.ejpb.2022.11.025_b0295","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/biomedicines9040365","article-title":"Hepatic stellate cell activation and inactivation in NASH-fibrosis\u2014Roles as putative treatment targets?","volume":"9","author":"Zisser","year":"2021","journal-title":"Biomedicines."},{"key":"10.1016\/j.ejpb.2022.11.025_b0300","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/jpet.108.144600","article-title":"Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet","volume":"328","author":"Kong","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2022.11.025_b0305","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lfs.2018.04.049","article-title":"Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance \u2014 A review","volume":"203","author":"Saini","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.ejpb.2022.11.025_b0310","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/S0022-2275(20)41084-3","article-title":"Reevaluation of the pathways for the biosynthesis of polyunsaturated fatty acids","volume":"36","author":"Sprecher","year":"1995","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejpb.2022.11.025_b0315","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jb\/mvt048","article-title":"Generation of membrane diversity by lysophospholipid acyltransferases","volume":"154","author":"Shindou","year":"2013","journal-title":"J. Biochem."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122002843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122002843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:49:30Z","timestamp":1760546970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641122002843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":63,"alternative-id":["S0939641122002843"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.11.025","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formulating elafibranor and obeticholic acid with phospholipids decreases drug-induced association of SPARC to extracellular vesicles from LX-2 human hepatic stellate cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}